Molecular mechanisms of cisplatin resistance
- PMID: 21892204
- DOI: 10.1038/onc.2011.384
Molecular mechanisms of cisplatin resistance
Abstract
Platinum-based drugs, and in particular cis-diamminedichloroplatinum(II) (best known as cisplatin), are employed for the treatment of a wide array of solid malignancies, including testicular, ovarian, head and neck, colorectal, bladder and lung cancers. Cisplatin exerts anticancer effects via multiple mechanisms, yet its most prominent (and best understood) mode of action involves the generation of DNA lesions followed by the activation of the DNA damage response and the induction of mitochondrial apoptosis. Despite a consistent rate of initial responses, cisplatin treatment often results in the development of chemoresistance, leading to therapeutic failure. An intense research has been conducted during the past 30 years and several mechanisms that account for the cisplatin-resistant phenotype of tumor cells have been described. Here, we provide a systematic discussion of these mechanism by classifying them in alterations (1) that involve steps preceding the binding of cisplatin to DNA (pre-target resistance), (2) that directly relate to DNA-cisplatin adducts (on-target resistance), (3) concerning the lethal signaling pathway(s) elicited by cisplatin-mediated DNA damage (post-target resistance) and (4) affecting molecular circuitries that do not present obvious links with cisplatin-elicited signals (off-target resistance). As in some clinical settings cisplatin constitutes the major therapeutic option, the development of chemosensitization strategies constitute a goal with important clinical implications.
Similar articles
-
Cisplatin: mode of cytotoxic action and molecular basis of resistance.Oncogene. 2003 Oct 20;22(47):7265-79. doi: 10.1038/sj.onc.1206933. Oncogene. 2003. PMID: 14576837 Review.
-
Failure of activation of caspase-9 induces a higher threshold for apoptosis and cisplatin resistance in testicular cancer.Cancer Res. 2003 Jan 15;63(2):513-21. Cancer Res. 2003. PMID: 12543810
-
Decreased accumulation as a mechanism of resistance to cis-diamminedichloroplatinum(II) in cervix carcinoma HeLa cells: relation to DNA repair.Mol Pharmacol. 1994 Jun;45(6):1137-44. Mol Pharmacol. 1994. PMID: 8022407
-
Cisplatin and platinum drugs at the molecular level. (Review).Oncol Rep. 2003 Nov-Dec;10(6):1663-82. Oncol Rep. 2003. PMID: 14534679 Review.
-
Gene-specific repair of Pt/DNA lesions and induction of apoptosis by the oral platinum drug JM216 in three human ovarian carcinoma cell lines sensitive and resistant to cisplatin.Br J Cancer. 1999 Dec;81(8):1294-303. doi: 10.1038/sj.bjc.6694381. Br J Cancer. 1999. PMID: 10604725 Free PMC article.
Cited by
-
Ferroptosis in cancer (Review).Oncol Lett. 2024 May 8;28(1):304. doi: 10.3892/ol.2024.14437. eCollection 2024 Jul. Oncol Lett. 2024. PMID: 38774452 Free PMC article. Review.
-
Integrins as the pivotal regulators of cisplatin response in tumor cells.Cell Commun Signal. 2024 May 13;22(1):265. doi: 10.1186/s12964-024-01648-0. Cell Commun Signal. 2024. PMID: 38741195 Free PMC article. Review.
-
Deciphering the Molecular Mechanisms behind Drug Resistance in Ovarian Cancer to Unlock Efficient Treatment Options.Cells. 2024 May 4;13(9):786. doi: 10.3390/cells13090786. Cells. 2024. PMID: 38727322 Free PMC article. Review.
-
Targeting ferroptosis as a potential strategy to overcome the resistance of cisplatin in oral squamous cell carcinoma.Front Pharmacol. 2024 Apr 22;15:1402514. doi: 10.3389/fphar.2024.1402514. eCollection 2024. Front Pharmacol. 2024. PMID: 38711989 Free PMC article. Review.
-
Drug resistance mechanisms and treatment strategies mediated by Ubiquitin-Specific Proteases (USPs) in cancers: new directions and therapeutic options.Mol Cancer. 2024 May 3;23(1):88. doi: 10.1186/s12943-024-02005-y. Mol Cancer. 2024. PMID: 38702734 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials
Miscellaneous